Tesamorelin

Tesamorelin is understood to bind the growth-hormone-releasing-hormone receptor (GHRHR), a G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary. As a stabilized GHRH analog, it engages this receptor to encourage the pituitary's intrinsic release of growth hormone rather than introducing exogenous hormone directly. Its modified structure is understood to give greater resistance to enzymatic degradation, which may extend its interaction with the target receptor.

Upon GHRHR engagement, the Gs-alpha subunit is activated and adenylyl cyclase is stimulated, raising intracellular cyclic AMP and activating protein kinase A. This signaling cascade is understood to increase transcription and pulsatile secretion of growth hormone from somatotrophs. The downstream rise in growth hormone is, in turn, associated with hepatic IGF-1 production, a pathway physicians commonly monitor when evaluating GHRH-analog activity.

Because the GHRH axis originates in the hypothalamus, tesamorelin is understood within the broader hypothalamic-pituitary signaling network rather than as a primarily neuroactive compound. Limited direct neural activity is described beyond its participation in this neuroendocrine feedback loop, and any cognitive or sleep-related observations remain preliminary and are not established outcomes.

Tesamorelin is most associated with metabolic and body-composition parameters, particularly its relationship to visceral adipose tissue. It is understood to shift lipid markers and lipolytic activity in a way attributed to restored, more physiologic growth hormone pulsatility. Because the compound works through the body's own feedback mechanisms, it is understood to preserve some of the natural regulatory checks of the GH/IGF-1 axis, an aspect not yet fully established.